PubMed COVID-19 Clinical Care

BACKGROUND: People with end-stage kidney disease, including people on haemodialysis, are susceptible to greater COVID-19 related morbidity and mortality. This study compares the immunogenicity and clinical effectiveness of BNT162B2 versus ChAdOx1 in

Background COVID-19 has become a public health emergency caused by a negative-stranded ribonucleic acid (RNA) virus, which previously caused severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS). In addition, the

The authors present three cases of unvaccinated coronavirus disease 2019 (COVID-19) patients who exhibited symptoms of fever, sore throat, nausea, diarrhea, congestion, and headache. Although they refused COVID-19 vaccination, they presented for the

By the end of 2019, a novel strain of the corona viral family named SARS-CoV-2 emerged in Wuhan, China and started to spread worldwide causing one of the most dangerous lethal pandemics. Researchers utilized various reported inhibitors and drug

The mathematical modeling of the coronavirus disease-19 (COVID-19) pandemic has been attempted by a large number of researchers from the very beginning of cases worldwide. The purpose of this research work is to find and classify the modelling of

Background The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the coronavirus disease 2019 (COVID-19), is behind the current pandemic. At the start of the pandemic, gastrointestinal symptoms initially described as

CONCLUSIONS: SARS-CoV-2 virus can affect any part of the digestive system. Patients with chronic diseases are at greatest risk of adverse out-comes. There is a considerable risk for drug-drug interactions in patients who require a large treatment

CONCLUSIONS: Clinicians should stay aware of potential new adverse events after immunization.

INTRODUCTION: Since the onset of COVID-19, physicians and scientists have been working to further understand biomarkers associated with the infection, so that patients who have contracted the virus can be treated. Although COVID-19 is a complex

We aimed to evaluate the seroconversion rates after two doses of inactive COVID-19 vaccine (CoronaVac) and the benefit of a third dose mRNA vaccine booster in patients with cancer receiving active treatment. Patients with solid tumors receiving